• Aconitase Assays in CD8+ T-Cell Metabolism

  2026-10-05

  A source-grounded overview of how aconitase activity measurements may complement research on CD8+ T-cell metabolism. The discussion distinguishes the direct findings of Holling et al. on the CD28–ARS2–PKM2 axis from supplier-described capabilities of the APExBIO Aconitase Activity Colorimetric Assay Kit, while defining evidence limits, interpretation boundaries, and the need for orthogonal metabolic measurements.

• Heat-Not-Burn Toxicity: Evidence and Limits

  2026-10-05

  Fu and colleagues compared the cytotoxicity and genotoxicity of a heat-not-burn product with conventional cigarette smoke across rat and cell-based models. The study’s main contribution is a comparative, multi-endpoint framework showing lower toxicity for the tested heat-not-burn product under the investigated conditions, while also demonstrating why those findings should not be interpreted as evidence of harmlessness or universal risk reduction.

• SETD7, White Adipose Browning, and T3 Research

  2026-10-04

  A 2026 study identifies SETD7 as a negative regulator of inguinal white adipose thermogenesis and links its depletion to an Adcy7–Sirt1–CREB1 pathway. The findings strengthen the case for studying adipocyte-intrinsic epigenetic control in metabolic disorder research, while remaining preclinical and distinct from direct evidence about Triiodothyronine or thyroid hormone receptor activation.

• CA-074 Me and the Lysosomal Necroptosis Frontier

  2026-10-03

  A source-grounded perspective on how cathepsin B inhibition can clarify lysosomal membrane permeabilization, necroptosis, apoptosis, and inflammatory disease models—while defining the evidence limits of chemical perturbation.

• AR Heterogeneity Shapes Castration and Enzalutamide Response

  2026-10-01

  Li and colleagues showed that heterogeneous androgen receptor expression is not merely a pathological feature of advanced prostate cancer but a determinant of castration and enzalutamide response. By combining patient samples, engineered cell models, xenografts, RNA sequencing, and combination treatment studies, the work distinguished AR-positive and AR-low or negative resistance states and identified BCL-2 as a therapeutic vulnerability.

• Ciclesonide: Translational Precision in a Degrader Era

  2026-10-01

  Ciclesonide illustrates how prodrug activation, intracellular retention, and glucocorticoid receptor pharmacology can sharpen respiratory research. This thought-leadership perspective connects that translational logic with ERAD-engaging targeted protein degradation while clearly distinguishing established evidence from forward-looking strategy.

• SNAI1, EMT, and Stemness in Thymic Tumors

  2026-10-01

  This 2024 study identifies SNAI1 as a central transcriptional regulator of epithelial–mesenchymal transition and cancer stem cell-like behavior in thymic epithelial tumors. Integrated genomic, epigenomic, single-cell, biochemical, and functional analyses connect SNAI1 to the PIK3R2/p-EphA2–GSK3β/β-catenin axis, while also implicating macrophage-state remodeling in the tumor microenvironment.

• Sulfaphenazole Restores Vasodilation in Diabetic Mice

  2026-09-30

  The reference study showed that inhibiting CYP2C with Sulfaphenazole restored acetylcholine-dependent endothelial relaxation in db/db diabetic mice without lowering plasma glucose. Its results link CYP-derived reactive oxygen species to reduced nitric oxide bioavailability, offering a mechanistic framework for vascular endothelial function research while leaving isoform specificity and clinical translation unresolved.

• AI-10-49: A Causal Assay Framework for inv(16) AML

  2026-09-29

  AI-10-49 is a selective CBFβ-SMMHC inhibitor that enables a layered investigation of fusion-protein engagement, RUNX1 reactivation, and leukemia dependence. This guide translates the inv(16) AML evidence base into practical assay decisions without treating downstream biomarkers as substitutes for target engagement.

• SETD7 Depletion Promotes Adipose Browning in Obesity

  2026-09-29

  This study identifies SETD7 as a negative regulator of inguinal white adipose tissue thermogenesis. Using mouse models, beige adipocyte cultures, and RNA-seq, the authors link SETD7 deficiency to an Adcy7–Sirt1–CREB1 pathway that enhances browning and improves resistance to high-fat diet-associated metabolic dysfunction.

• Chlorpromazine Beyond D2: A Translational Lens

  2026-09-28

  Chlorpromazine offers more than a familiar dopamine D2 receptor antagonist model. This thought-leadership analysis connects its multi-receptor pharmacology with emerging evidence on hepatic nanoparticle interactions, helping translational researchers distinguish validated biology from testable opportunity in antipsychotic research and nanomedicine.

• SNAI1 Links EMT and Stemness in Thymic Tumors

  2026-09-28

  A 2024 study identifies SNAI1 as a regulator of epithelial–mesenchymal transition and cancer stem cell-like traits in thymic epithelial tumors, connecting its transcriptional activity to PIK3R2 and phosphorylated EphA2. The combined genomic, cellular, animal, and molecular assays support a proposed signaling mechanism, while leaving therapeutic translation and clinical relevance to be tested.

• LY2886721: BACE Inhibitor Evidence and Research Use

  2026-09-27

  LY2886721 is an oral BACE inhibitor reported to suppress BACE1 activity and amyloid beta production in cellular and animal models. Evidence from neuronal cultures indicates that the effect of partial BACE inhibition on synaptic transmission depends on the degree of amyloid beta reduction, so model-specific validation is essential.

• SNAI1–PIK3R2/p-EphA2 Signaling in Thymic Tumors

  2026-09-26

  A 2024 study identifies SNAI1 as a driver of epithelial–mesenchymal transition (EMT) and cancer stem cell-like traits in thymic epithelial tumors, connecting its transcriptional activity to PIK3R2 and phosphorylated EphA2. Multi-omics and functional experiments support this signaling model and suggest SNAI1 as a candidate therapeutic target, while leaving its clinical relevance and drug-response implications to be tested.

• SNAI1–PIK3R2 Signaling in Thymic Epithelial Tumors

  2026-09-25

  A 2024 study identifies SNAI1 as a transcriptional hub associated with invasive thymic epithelial tumors and links it to EMT, cancer stem cell-like traits, and macrophage-state changes. Its proposed mechanism connects transcriptional regulation of PIK3R2 with phosphorylated EphA2 and downstream GSK3β/β-catenin signaling, offering a framework for further testing rather than an established treatment strategy.

7974 records 1/532 page Next 12345 下5页 Last page